πŸ‡ΊπŸ‡Έ FDA
Patent

US 11220488

Crystalline polymorph of Ponesimod

granted A61KA61K31/426A61P

Quick answer

US patent 11220488 (Crystalline polymorph of Ponesimod) held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Grant date
Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/426, A61P, A61P17/06, A61P25/14